Multicenter Randomized Double-Blind, Placebo-Controlled Trial GORTEC (Groupe Oncologie Radiotherapie Tete et Cou) 2009-01 Evaluating the Effect of the Regenerating Agent on Radiodermatitis of Head and Neck Cancer Patients

2017 ◽  
Vol 99 (3) ◽  
pp. 590-595 ◽  
Author(s):  
Yungan Tao ◽  
Anne Auperin ◽  
Christian Sire ◽  
Michel Martin ◽  
Marie-Gabrielle Saliou ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Tête Et Cou

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

The Lancet ◽  
2003 ◽  
Vol 362 (9392) ◽  
pp. 1255-1260 ◽  
Author(s):  
Michael Henke ◽  
Roland Laszig ◽  
Christian Rübe ◽  
Ulrich Schäfer ◽  
Klaus-Dieter Haase ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals OC-0631 Stem cell sparing IMRT for head and neck cancer patients: a double-blind randomized controlled trial

2019 ◽  
Vol 133 ◽  
pp. S335-S336
Author(s):  
R. Steenbakkers ◽  
M. Stokman ◽  
R. Kierkels ◽  
M. Schuurman ◽  
A. Van den Hoek ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Head And Neck Cancer ◽  
Stem Cell ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Double Blind ◽  
Randomized Controlled

scholarly journals A Randomized Double-Blind Placebo-Controlled Trial of Fruit and Vegetable Concentrates on Intermediate Biomarkers in Head and Neck Cancer

2017 ◽  
Vol 17 (1) ◽  
pp. 115-123
Author(s):  
Mridul Datta ◽  
Edward G. Shaw ◽  
Glenn J. Lesser ◽  
L. Douglas Case ◽  
Mara Z. Vitolins ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Controlled Trial ◽  
Second Primary ◽  
Double Blind ◽  
Ki 67 ◽  
Primary Tumors ◽  
Double Blind Placebo ◽  
Increased Risk

Background. Head and neck cancer (HNC) patients are at an increased risk for developing second primary tumors (SPTs). Diets rich in fruits and vegetables (FVs) may lower HNC risk. FV concentrates may offer a potential alternative to increasing FV intake. Methods. We conducted a randomized, double-blind, placebo-controlled trial to evaluate whether Juice PLUS+ (JP; a commercial product with multiple FV concentrates) has an effect on p27 and Ki-67, biomarkers associated with the risk of SPTs. During 2004-2008, we randomized 134 HNC patients to 12 weeks of JP (n = 72) or placebo (n = 62). Oral cavity mucosal biopsies and whole blood were obtained at baseline and after 12 weeks. All participants were given the opportunity to receive JP for 5 years following the end of the intervention period, and they were followed yearly for the development of SPTs. Results. After 12 weeks, patients on JP had significantly higher serum α-carotene ( P = .009), β-carotene ( P < .0001), and lutein ( P = .003) but did not differ significantly in p27 ( P = .23) or Ki-67 ( P = .95). JP use following the initial 12-week trial was not significantly associated with SPT prevention. Conclusions. Despite increased serum micronutrient levels, our results do not suggest a clinical benefit of JP in HNC patients. Future studies should focus on longer intervention periods and/or modified supplement formulations with demonstrated chemopreventive properties.

Sign in / Sign up

Export Citation Format

Share Document